| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(05)67101-2 |
| P698 | PubMed publication ID | 16099293 |
| P2093 | author name string | Jean-François Bosset | |
| Laurence Collette | |||
| Karin Haustermans | |||
| Michel Bolla | |||
| Roland van Velthoven | |||
| Luigi Da Pozzo | |||
| European Organization for Research and Treatment of Cancer | |||
| Hein van Poppel | |||
| Pierre Scalliet | |||
| Theo M de Reijke | |||
| Kris Vekemans | |||
| Marianne Piérart | |||
| Antony Verbaeys | |||
| Jean-Marie Maréchal | |||
| Paul van Cangh | |||
| P2860 | cites work | Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer | Q34719575 |
| Postoperative Radiotherapy after Prostatectomy A Review | Q35127014 | ||
| Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. | Q40389158 | ||
| Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run. | Q40636569 | ||
| Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns | Q41709393 | ||
| Adjuvant radiation therapy after radical prostatectomy for carcinoma of the prostate | Q46125962 | ||
| Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate | Q59364633 | ||
| External-bean megavoltage radiation therapy in the treatment of post-radical prostatectomy residual or recurrent tumor preliminary results | Q67509902 | ||
| The Effect of Radiation Therapy after Radical Prostatectomy in Patients with Elevated Prostate Specific Antigen Levels | Q67670426 | ||
| The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer | Q71058228 | ||
| Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update | Q71705909 | ||
| Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: Analysis of freedom from psa failure | Q72096132 | ||
| Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer | Q73250827 | ||
| Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy | Q73383413 | ||
| Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer | Q73551672 | ||
| Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy | Q73728114 | ||
| Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy | Q73886350 | ||
| Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study | Q73944624 | ||
| (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy | Q74144672 | ||
| Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial | Q74786331 | ||
| The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis | Q78222739 | ||
| Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features | Q81396387 | ||
| P433 | issue | 9485 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | randomized controlled trial | Q1436668 |
| P304 | page(s) | 572-578 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) | |
| P478 | volume | 366 |
| Q57133489 | Q57133489 |
| Q57136335 | Q57136335 |
| Q53018341 | (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy. |
| Q39594730 | A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer |
| Q40120703 | A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. |
| Q37258361 | A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies |
| Q26800823 | A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer |
| Q47825566 | A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. |
| Q37452750 | ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours |
| Q60369027 | Ability of Linear Length of Positive Margin in Radical Prostatectomy Specimens to Predict Biochemical Recurrence |
| Q90157557 | Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: A meta-analysis |
| Q30278648 | Adjuvant and salvage radiation therapy after prostatectomy: investigating beliefs and practices of radiation oncologists |
| Q28541950 | Adjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis |
| Q84984714 | Adjuvant and salvage radiotherapy after prostatectomy: outcome analysis of 307 patients with prostate cancer |
| Q36740128 | Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy |
| Q34179268 | Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study |
| Q34013808 | Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials |
| Q100407571 | Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data |
| Q37446036 | Adjuvant radiation therapy after radical prostatectomy: when is it indicated? |
| Q33582634 | Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG. |
| Q24234347 | Adjuvant radiotherapy following radical prostatectomy for prostate cancer |
| Q24242552 | Adjuvant radiotherapy following radical prostatectomy for prostate cancer |
| Q36710328 | Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement |
| Q37019386 | Adjuvant radiotherapy for high-risk patients following radical prostatectomy |
| Q89520890 | Adjuvant radiotherapy in prostate cancer patients with positive margins or extracapsular extension |
| Q80682566 | Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database |
| Q84739597 | Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: postprostatectomy adjuvant radiotherapy: a SEER analysis |
| Q100407589 | Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial |
| Q55456247 | Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: comparative analysis of long-term outcomes. |
| Q38699141 | Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database. |
| Q57461685 | Adjuvant vs. salvage radiation therapy in men with high-risk features after radical prostatectomy: Survey of North American genitourinary expert radiation oncologists |
| Q36201978 | Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes |
| Q42364621 | African-american race is a predictor of seminal vesicle invasion after radical prostatectomy |
| Q39844344 | Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort |
| Q34111603 | Androgen deprivation therapy for prostate cancer-review of indications in 2010 |
| Q37735433 | Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence |
| Q35777574 | Artificial urinary sphincter erosion after radical prostatectomy in patients treated with and without radiation |
| Q37377699 | Assessing guideline impact on referral patterns of post-prostatectomy patients to radiation oncologists |
| Q83815790 | Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment |
| Q50066944 | Biopsy Core Features Are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer |
| Q63966244 | Bulletin de synthèse de veille 2005 Recommandations pour la pratique clinique |
| Q43440505 | CCAFU Recommendations 2013: Prostate cancer |
| Q37938241 | Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling |
| Q57566962 | Cancer de la prostate |
| Q46467822 | Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer |
| Q42660306 | Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy |
| Q57112428 | Chemotherapy and radiation for prostate cancer |
| Q42136094 | Clarifying the role of salvage radiotherapy. |
| Q41948939 | Clinical significance of surgical margin status in patients subjected to radical prostatectomy |
| Q37706802 | Clinical significance of the positive surgical margin based upon location, grade, and stage |
| Q33722746 | Clinician-led improvement in cancer care (CLICC)--testing a multifaceted implementation strategy to increase evidence-based prostate cancer care: phased randomised controlled trial--study protocol |
| Q45258653 | Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy |
| Q40640513 | Close surgical margins after radical prostatectomy mimic biochemical recurrence rates of positive margins. |
| Q90748143 | Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study |
| Q87549689 | Commentary on "Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)." Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verb |
| Q90018871 | Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting |
| Q47645461 | Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features |
| Q42707354 | Comparison of Pathological Outcomes for Men with Low Risk Prostate Cancer from Diverse Practice Settings: Similar Results from Immediate Prostatectomy or Initial Surveillance with Delayed Prostatectomy |
| Q37339685 | Comparison of models to predict clinical failure after radical prostatectomy |
| Q40625979 | Complications and functional results of surgery for locally advanced prostate cancer. |
| Q41420388 | Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer |
| Q35141139 | Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy |
| Q41895292 | Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients |
| Q48756250 | Contemporary Patterns of Care and Outcomes of Men Found to Have Lymph Node Metastases at the Time of Radical Prostatectomy |
| Q37738788 | Contemporary management of high-risk localized prostate cancer |
| Q34211155 | Contemporary role of androgen deprivation therapy for prostate cancer |
| Q41822113 | Continuous prostate-specific antigen rise despite salvage radiotherapy following radical prostatectomy: Pattern of clinical relapse and predictive factors |
| Q51731303 | Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment. |
| Q35902806 | Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis. |
| Q52568037 | Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. |
| Q33710312 | Counseling patients about sexual health when considering post-prostatectomy radiation treatment |
| Q34346841 | Current status of radical prostatectomy for high-risk prostate cancer. |
| Q37463713 | Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients |
| Q80429102 | Defining the appropriate measure of success for adjuvant radiation following prostatectomy |
| Q36859714 | Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group |
| Q42916506 | Definition and visualisation of regions of interest in post-prostatectomy image-guided intensity modulated radiotherapy |
| Q91757114 | Definition of fields margins for the optimized 2D radiotherapy of prostate carcinoma |
| Q60920436 | Definitive external-beam radiotherapy versus radical prostatectomy in clinically localized high-risk prostate cancer: a retrospective study |
| Q39288342 | Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis |
| Q36762398 | Development and validation of a 32-gene prognostic index for prostate cancer progression |
| Q33761075 | Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer |
| Q38109258 | Developments in external beam radiotherapy for prostate cancer |
| Q46927098 | Differential therapy of prostate cancer |
| Q63966249 | Difficult clinical cases in prostate cancer: multidisciplinary staff, the rational principles of adjuvant therapy and other therapeutic options |
| Q28534277 | Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy |
| Q51019331 | Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. |
| Q58549683 | Dosimetric and volumetric effects in clinical target volume and organs at risk during postprostatectomy radiotherapy |
| Q84099107 | Dr. Izawa's rebuttal |
| Q85226513 | Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy |
| Q56910933 | Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study |
| Q34725046 | Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence |
| Q43483287 | Early postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer. Long-term results of the EORTC trial 22911 |
| Q42030197 | Editorial Comment on adjuvant radiotherapy study |
| Q28554583 | Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical Prostatectomy |
| Q35211723 | Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery |
| Q30405851 | Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis |
| Q40178727 | Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT. |
| Q41608624 | Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups. |
| Q50074965 | First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database |
| Q54346665 | GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy. |
| Q26751574 | Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life |
| Q36281753 | General commentary to the "management of biochemical recurrence after primary localized therapy for prostate cancer" by darwish o. M. And raj g. V |
| Q35771477 | Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers |
| Q36945088 | Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy |
| Q30371634 | Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy |
| Q37485229 | Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial |
| Q35869811 | High-risk prostate cancer-classification and therapy |
| Q36842377 | High-risk, clinically localized prostate cancer: is monotherapy adequate? |
| Q46748035 | How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome |
| Q34462816 | Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trial |
| Q38283897 | Hypofractionated radiotherapy for prostate cancer. |
| Q48213603 | Impact of Gleason score on biochemical recurrence in patients with pT3aN0/Nx prostate cancer with positive surgical margins: a multicenter study from the Prostate Cancer Research Committee. |
| Q39248297 | Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml |
| Q36581481 | Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). |
| Q37579088 | Impact of positive surgical margins on biochemical relapse after radical retropubic prostatectomy (RRP). |
| Q50773677 | Impact of radical prostatectomy positive surgical margins on fear of cancer recurrence: results from CaPSURE. |
| Q36765820 | Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer |
| Q42571904 | Intensified adjuvant treatment of prostate carcinoma: feasibility analysis of a phase I/II trial |
| Q55129526 | Intermittent, low-dose, antiandrogen monotherapy as an alternative therapeutic option for patients with positive surgical margins after radical prostatectomy. |
| Q33660380 | International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer |
| Q58694957 | International validation of the EORTC QLQ-PRT20 module for assessment of quality of life symptoms relating to radiation proctitis: a phase IV study |
| Q50062202 | Interobserver variation in target volume for salvage radiotherapy in recurrent prostate cancer patients after radical prostatectomy using CT versus combined CT and MRI: a multicenter study (KROG 13-11). |
| Q37377708 | Is it time to end lone-wolf medicine? |
| Q37788799 | Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer? |
| Q79520905 | Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes |
| Q57105378 | Landmarks in prostate cancer |
| Q35231126 | Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database |
| Q37261953 | Local-regional prostate cancer |
| Q35850867 | Locally advanced prostate cancer: a population-based study of treatment patterns |
| Q92718589 | Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy |
| Q87133272 | Location, extent, and multifocality of positive surgical margins for biochemical recurrence prediction after radical prostatectomy |
| Q50499932 | Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin. |
| Q42625963 | Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era. |
| Q38248286 | Long-term complications in men who have early or late radiotherapy after radical prostatectomy |
| Q42049239 | Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. |
| Q34325482 | Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy |
| Q36100502 | Low detectable prostate specific antigen after radical prostatectomy--treat or watch? |
| Q34778720 | Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features |
| Q45958218 | Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. |
| Q47972104 | Lymphadenectomy in Gleason 7 prostate cancer: Adherence to guidelines and effect on clinical outcomes |
| Q46715471 | Lymphovascular invasion is significantly associated with biochemical relapse after radical prostatectomy even in patients with pT2N0 negative resection margin |
| Q90053605 | MRI-Derived Radiomics to Guide Post-operative Management for High-Risk Prostate Cancer |
| Q79799201 | Management of biochemical failure following radical prostatectomy: salvage radiotherapy - a case series |
| Q35503645 | Management of high-risk localized prostate cancer |
| Q37074747 | Management of locally advanced prostate cancer |
| Q26849220 | Management of patients with biochemical recurrence after local therapy for prostate cancer |
| Q38157338 | Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. |
| Q40258902 | Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain |
| Q36448693 | Management of prostate cancer. Part 2: localized and locally advanced disease |
| Q40813644 | Margin details matter: The prognostic significance of pseudocapsule invasion at the site of involved margin in prostatectomy specimens |
| Q35925712 | Meta-analysis of the effect of postoperative radiotherapy on prognosis of prostatic cancer following radical prostatectomy |
| Q33373839 | Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. |
| Q34111597 | Multimodal Approaches to High-Risk Prostate Cancer |
| Q37691629 | Neoadjuvant and adjuvant therapies in prostate cancer |
| Q46727594 | Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer |
| Q37823204 | Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer |
| Q40281680 | New techniques and management options for localized prostate cancer. |
| Q64968619 | Nonuniform Planning Target Volume Margins for Prostate Bed on the Basis of Surgical Clips on Daily Cone Beam Computed Tomography. |
| Q83989911 | Obesity and survival after radical prostatectomy: A 10-year prospective cohort study |
| Q84961250 | Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate |
| Q44096432 | Oncologic outcomes after minimally invasive radical prostatectomy in patients with seminal vesicle invasion (pT3b) without adjuvant therapy |
| Q44991712 | Opinions from the experts: exploring what prostate cancer patients should know about post-operative radiotherapy |
| Q41984611 | Opportunity lost and found: Any easy way to improve outcomes for prostate cancer patients in the postoperative setting? |
| Q26801188 | Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy |
| Q54468685 | Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. |
| Q34325452 | Outcome of postoperative radiotherapy following radical prostatectomy: a single institutional experience |
| Q82599545 | Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy |
| Q47105326 | Outcomes of post-prostatectomy radiotherapy at a Regional Cancer Centre |
| Q36520539 | Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? |
| Q53454940 | PET/CT imaging of recurrent prostate cancer. |
| Q79794781 | Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote |
| Q38996907 | Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography |
| Q36329095 | Pelvic radiation therapy: Between delight and disaster |
| Q36761288 | Percutaneous radiotherapy for low-risk prostate cancer: options for 2007. |
| Q42261756 | Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer |
| Q46614689 | Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). |
| Q37427663 | Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy |
| Q46749982 | Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer |
| Q84780836 | Place of surgery in high-risk tumours of the prostate |
| Q37903116 | Positive margins after radical prostatectomy: implications for failure and role of adjuvant treatment |
| Q90181676 | Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors |
| Q42630674 | Positive surgical margins at radical prostatectomy: Population-based averages within PSA and Gleason strata |
| Q44108889 | Positive surgical margins at radical prostatectomy: much ado about nothing? |
| Q41718014 | Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort |
| Q50238254 | Post-prostatectomy radiotherapy adversely affects urinary continence irrespective of radiotherapy regime |
| Q51943856 | Post-radical prostatectomy management options for positive surgical margins: argument for observation. |
| Q37359283 | Post-radical prostatectomy management options for the positive surgical margin: argument for adjuvant radiotherapy |
| Q61731330 | Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial |
| Q36439622 | Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy |
| Q33705993 | Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases |
| Q63966469 | Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) |
| Q35863963 | Postoperative radiotherapy after radical prostatectomy: indications and open questions |
| Q50002077 | Postoperative radiotherapy for prostate cancer : Morbidity of local-only or local-plus-pelvic radiotherapy |
| Q52937150 | Postoperative radiotherapy for prostate cancer. |
| Q43154723 | Postoperative radiotherapy in prostate cancer: Analysis of prognostic factors in a series of 282 patients. |
| Q37324245 | Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial |
| Q46127804 | Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE database |
| Q37161554 | Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy |
| Q92137487 | Prediction of Postprostatectomy Biochemical Recurrence Using Quantitative Ultrasound Shear Wave Elastography Imaging |
| Q80733891 | Predictors of biochemical progression-free survival in men who receive radiation therapy after prostatectomy |
| Q26783861 | Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model |
| Q102060643 | Prognostic classifier for predicting biochemical recurrence in localized prostate cancer patients after radical prostatectomy |
| Q95789771 | Prognostic factors for failure after prostatectomy |
| Q34091402 | Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy |
| Q40619712 | Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy |
| Q81819953 | Prognostic significance of cancer volume involving seminal vesicles in patients with pT3bpN0 prostate cancer |
| Q90579464 | Prognostic significance of lymphovascular invasion in patients with prostate cancer treated with postoperative radiotherapy |
| Q35167186 | Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis |
| Q54075309 | Prostate bed target interfractional motion using RTOG consensus definitions and daily CT on rails : Does target motion differ between superior and inferior portions of the clinical target volume? |
| Q81295804 | Prostate cancer |
| Q37097495 | Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes |
| Q33887010 | Prostate cancer radiotherapy in Austria: overview on number of patients, intention to treat, and treatment techniques based on data from 2007. |
| Q42848548 | Prostate cancer screening: Canadian guidelines 2011 |
| Q41689133 | Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA. |
| Q34794205 | Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy |
| Q45934623 | Prostate cancer: Benefit and safety of adjuvant radiation therapy. |
| Q83787762 | Prostate cancer: local control and radiotherapy matter in prostate cancer |
| Q39136011 | Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer |
| Q43429179 | Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence |
| Q40636362 | Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer. |
| Q46642565 | Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy |
| Q26744531 | Radiation Therapy after Radical Prostatectomy: Implications for Clinicians |
| Q34111590 | Radiation Therapy in Prostate Cancer: A Risk-Adapted Strategy |
| Q30300626 | Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort |
| Q37446029 | Radiation therapy approaches to the treatment of high-risk prostate cancer |
| Q37889109 | Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage? |
| Q44358760 | Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy |
| Q46477320 | Radiation therapy for urologic malignancies in the elderly |
| Q42103015 | Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL. |
| Q35779513 | Radical prostatectomy and intraoperative radiation therapy in high-risk prostate cancer. |
| Q37982319 | Radical prostatectomy as primary treatment of high-risk prostate cancer |
| Q46509230 | Radical prostatectomy for cT3–4 disease: an evaluation of the pathological outcomes and patterns of care for adjuvant radiation in a national cohort |
| Q83340937 | Radical prostatectomy for clinical T4 prostate cancer |
| Q35605772 | Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. |
| Q36841565 | Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial |
| Q38684701 | Radical prostatectomy: an option for high-risk prostate cancer |
| Q37975659 | Radical prostatectomy: positive surgical margins matter |
| Q51949895 | Radical prostatectomy: surgical planning, execution, and outcomes. |
| Q44905750 | Radiotherapy after radical prostatectomy: immediate or early delayed? |
| Q35041485 | Radiotherapy after radical prostatectomy: treatment recommendations differ between urologists and radiation oncologists |
| Q38278140 | Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer |
| Q33583944 | Radiotherapy in prostate cancer treatment: results of the patterns of care study in Korea |
| Q39238392 | Radiotherapy in the treatment of advanced and recurrent prostate cancer |
| Q84978525 | Radiotherapy of prostate cancer |
| Q42639555 | Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy |
| Q63966222 | Recommandations en Onco-Urologie 2010 : Cancer de la prostate |
| Q37581405 | Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score |
| Q51715296 | Risk of biochemical recurrence and timing of radiotherapy in pT3a N0 prostate cancer with positive surgical margin : A single center experience. |
| Q35231112 | Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database |
| Q42429784 | Role of Surgery in High-Risk Localized Prostate Cancer |
| Q35796878 | Role of Surgery in locally advanced prostate cancer |
| Q37951792 | Role of radiation therapy for the treatment of lymph nodes in urologic malignancies |
| Q34139187 | Role of radical prostatectomy for high-risk prostate cancer |
| Q37258850 | Role of radical prostatectomy in the treatment of high-risk prostate cancer |
| Q37216103 | Salvage radiotherapy after radical prostatectomy. |
| Q42264405 | Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy |
| Q33317042 | Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience |
| Q33766462 | Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges |
| Q42674283 | Salvage radiotherapy for prostate cancer: Finding a way forward using radiobiological modeling |
| Q47967585 | Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results |
| Q84582202 | Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer |
| Q54218117 | Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. |
| Q37216107 | Salvage versus adjuvant radiotherapy after radical prostatectomy: argument for adjuvant radiotherapy |
| Q34997355 | Saudi Oncology Society clinical management guidelines for prostate cancer. |
| Q26747782 | Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer |
| Q34437308 | Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. |
| Q33486265 | Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data |
| Q33754017 | Shared responsibility for treatment-related morbidity for prostate cancer |
| Q36805299 | Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. |
| Q38266018 | Significance and management of positive surgical margins at the time of radical prostatectomy |
| Q40420529 | Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. |
| Q35684509 | Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study |
| Q47114787 | Stability analysis on the radioactive iodine-labelled prostate cancer-specific recombinant oncolytic adenovirus |
| Q101564382 | Surgical management of high-risk, localized prostate cancer |
| Q56363448 | Tailored postoperative treatment of prostate cancer: final results of a phase I/II trial |
| Q39363908 | Target volume definition for post prostatectomy radiotherapy: Do the consensus guidelines correctly define the inferior border of the CTV? |
| Q37339472 | Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. |
| Q46765601 | The German S3 guideline prostate cancer: aspects for the radiation oncologist |
| Q53116910 | The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. |
| Q50919717 | The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. |
| Q85764244 | The association between nerve sparing and a positive surgical margin during radical prostatectomy |
| Q39717982 | The association between tumour density and prostate cancer recurrence following radical prostatectomy. |
| Q43650830 | The clinical significance of in-depth pathological assessment of extraprostatic extension and margin status in radical prostatectomies for prostate cancer |
| Q57809563 | The effect of surgery report cards on improving radical prostatectomy quality: the SuRep study protocol |
| Q41959515 | The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy |
| Q36090379 | The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer |
| Q36557988 | The importance of local control in high-risk locally advanced prostate cancer |
| Q35014945 | The multi-disciplinary management of high-risk prostate cancer |
| Q41435839 | The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence |
| Q86086576 | The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes |
| Q38591851 | The role for surgery in high-risk prostate cancer |
| Q51320797 | The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer. |
| Q36868337 | The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients |
| Q37873792 | The role of lymph node dissection in the management of prostate cancer |
| Q38193435 | The role of postoperative radiotherapy in prostate cancer patients |
| Q37270502 | The role of radical prostatectomy in high-risk prostate cancer |
| Q36801769 | The spectrum of prostate cancer care: from curative intent to palliation. |
| Q38211115 | The status of surgery in the management of high-risk prostate cancer |
| Q35296487 | The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy |
| Q38952181 | The very-high-risk prostate cancer: a contemporary update |
| Q42539752 | Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center |
| Q41862818 | Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis. |
| Q44922218 | Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. |
| Q100407566 | Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial |
| Q47144748 | Tissue-based biomarkers in prostate cancer |
| Q39247989 | Total error shift patterns for daily CT on rails image-guided radiotherapy to the prostate bed. |
| Q41987819 | Tracking tumor evolution via prostate-specific antigen: an individual post-operative study |
| Q80123932 | Treatment failure after primary and salvage therapy for prostate cancer |
| Q37671592 | Treatment strategies for high-risk locally advanced prostate cancer |
| Q30413727 | Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy |
| Q33754012 | Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer. |
| Q92442584 | Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor |
| Q87074723 | Trends in the use of postprostatectomy therapies for patients with prostate cancer: a surveillance, epidemiology, and end results Medicare analysis |
| Q51743377 | Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. |
| Q35924258 | Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy |
| Q28750702 | Ultrasensitive prostate specific antigen assay following laparoscopic radical prostatectomy--an outcome measure for defining the learning curve |
| Q58545136 | Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up |
| Q84710831 | Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer |
| Q53078458 | Using fiducial markers in the prostate bed in postprostatectomy external beam radiation therapy improves accuracy over surgical clips. |
| Q30912685 | Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme |
| Q83836280 | Utilization and expense of adjuvant cancer therapies following radical prostatectomy |
| Q30385364 | Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy. |
| Q87187663 | Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty |
| Q35630139 | Variations among experienced surgeons in cancer control after open radical prostatectomy |
| Q51039978 | Vesicourethral anastomosis during radical retropubic prostatectomy: does the number of sutures matter? |
| Q37136805 | Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer |
| Q54963843 | Volumetric and dosimetric comparison of organs at risk between the prone and supine positions in postoperative radiotherapy for prostate cancer. |
| Q39128150 | Volumetric image-guided highly conformal radiotherapy of the prostate bed: Toxicity analysis. |
| Q44095069 | What is the optimal management of high risk, clinically localized prostate cancer? |
| Q38191927 | What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision-making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer? |
| Q93659289 | What's new in the other general journals |
| Q80997886 | Which patients with prostate cancer benefit from immediate postoperative radiotherapy? |
| Q84739615 | Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy |
| Q42072377 | [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes |
| Q80767237 | [Adjuvant treatment after total prostatectomy] |
| Q80823343 | [Current treatment in high risk and locally advanced prostate cancer] |
| Q89723874 | [Early salvage radiation therapy of the prostate bed appears to be equally effective compared to adjuvant radiation therapy after radical prostatectomy] |
| Q79761988 | [High-dose rate brachytherapy for high-risk prostate cancer] |
| Q82728748 | [Postoperative radiotherapy for prostate cancer] |
| Q80286700 | [Prevention of local recurrence using adjuvant radiotherapy after radical prostatectomy. Indications, results, and side effects] |
| Q57142318 | [Prostate cancer: evidence based clinical practice] |
| Q50800434 | [Prostate cancer: synopsis of the American Urological Association (AUA) 2006] |
| Q85072187 | [Radiotherapy of prostate cancer] |
| Q79956697 | [Synthesis of the multidisciplinary consensus meeting on prostatic cancer] |
| Q82093778 | [The role of surgery in locally advanced prostate cancer] |
| Q84460959 | [Uro-oncology--update 2009] |
| Q46740533 | p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). |
| Q45230295 | pT3N0M0 prostate cancer: a plea for adjuvant radiation |
| Q44239064 | pT3R1 prostate cancer : Immediate or delayed radiotherapy after radical prostatectomy? |
Search more.